Trial document

PLEASE NOTE:
This study has been imported from ClinicalTrials.gov without additional data checks.

drksid header

DRKS-ID: DRKS00008008

Trial Description

start of 1:1-Block title

Title

Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus

end of 1:1-Block title

start of 1:1-Block acronym

Trial Acronym

ESOPEC

end of 1:1-Block acronym

start of 1:1-Block url

URL of the Trial

http://./.

end of 1:1-Block url

start of 1:1-Block public summary

Brief Summary in Lay Language

The trial is designed to investigate differences in outcome of patients with esophageal
adenocarcinoma and junctional adenocarcinoma treated with perioperative (neoadjuvant +
adjuvant) chemotherapy (FLOT) plus surgical resection versus neoadjuvant chemoradiation
(CROSS) plus surgical resection.

end of 1:1-Block public summary

start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

According to the given evidence a survival benefit of perioperative chemotherapy (periCTX)
over Neoadjuvant chemoradiation (neoCRT) for patients with Esophageal adenocarcinomas (EAC)
has not been proven in any randomized controlled trials (RCT). Data supporting the value of
periCTX have all been obtained in studies including mixed patient cohorts with EAC and
gastric adenocarcinoma (GAC). Due to relevant differences of histologic subtype
distribution, response to periCTX and survival rates between EAC and GAC there is a clear
need to obtain evidence concerning the value of periCTX for EAC. As nowadays periCTX is
extensively and successfully applied in clinical practice in patients with EAC there is an
obvious need to obtain evidence from a multicentre RCT. Moreover a confirmation of the
superior survival rates of the recent RCT on neoCRT should be obtained in a RCT conducted
exclusively on EAC. Therefore, this prospective RCT with the primary objective of longterm
patient survival comparing periCTX and neoCRT was designed.

end of 1:1-Block scientific synopsis

start of 1:1-Block organizational data

Organizational Data

DRKS-ID: DRKS00008008
Date of Registration in DRKS: 2015/09/03
Date of Registration in Partner Registry or other Primary Registry: 2015/07/22
Investigator Sponsored/Initiated Trial (IST/IIT): yes
Ethics Approval/Approval of the Ethics Committee: [---]*
(leading) Ethics Committee No.: [---]*

end of 1:1-Block organizational data

start of 1:n-Block secondary IDs

Secondary IDs

EudraCT-No. (for studies acc. to Drug Law): 2015-001683-20
Primary Registry-ID: NCT02509286 (ClinicalTrials.gov)
Sponsor-ID: P000760 (University Hospital Freiburg)

end of 1:n-Block secondary IDs

start of 1:N-Block indications

Health Condition or Problem studied

Free text: Esophageal Adenocarcinoma (UICC TNM7)
Free text: Adenocarcinoma of the Esophagogastric Junction
ICD10: C15 - Malignant neoplasm of oesophagus

end of 1:N-Block indications

start of 1:N-Block interventions

Interventions/Observational Groups

Arm 1: Drug: 5-Fluorouracil
Arm 2: Drug: Leucovorin
Arm 3: Drug: Oxaliplatin
Arm 4: Drug: Docetaxel
Arm 5: Drug: Carboplatin
Arm 6: Drug: Paclitaxel
Arm 7: Radiation: Neoadjuvant radiation

end of 1:N-Block interventions

start of 1:1-Block design

Characteristics

Study Type: Interventional
Study Type Non-Interventional: [---]*
Allocation: Randomized controlled trial
Blinding: Open (masking not used)
Who is blinded: [---]*
Control: Active control (effective treament of control group)
Purpose: Treatment
Assignment: Parallel
Phase: III
Off-label Drug use: [---]*

end of 1:1-Block design

start of 1:1-Block primary endpoint

Primary Outcome

- Overall survival; time frame: At end of trial- up to 3 years in follow up; Overall survival will be calculated as time from start of study treatment to death due to any cause.

end of 1:1-Block primary endpoint

start of 1:1-Block secondary endpoint

Secondary Outcome

- Progression free survival time (PFS); time frame: From randomisation up to 3 years in follow up; PFS will be calculated as the time interval from randomisation to the first event of locoregional failure, metastatic progression or death.
- Site of failure: local, regional or distant Failure; time frame: From time of surgery up to 3 years in follow up
- Recurrence free survival time; time frame: From time of surgery up to 3 years in follow up; RFS will be calculated in resected patients who achieved an R0 or R1 resection as the time interval from surgery to the date of first recurrence (local, regional or distant) or death, whatever comes first.
- Postsurgical Quality of Life; time frame: From randomization up to 3 years in follow up
- Postoperative complications; time frame: From time of surgery up to 90 days postoperatively
- Non-surgical site complications; time frame: From time of surgery up to 90 days postoperatively

end of 1:1-Block secondary endpoint

start of 1:n-Block recruitment countries

Countries of Recruitment

DE: Germany

end of 1:n-Block recruitment countries

start of 1:n-Block recruitment locations

Locations of Recruitment

Uniklinik RWTH Aachen, Aachen
Charité Berlin - Campus Benjamin Franklin (CBF), Berlin
Charité Berlin Campus Virchow-Klinikum (CVK), Berlin
Klinikum Dortmund gGmbH, Dortmund
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden
Universitätsklinikum Düsseldorf, Düsseldorf
Universitätsklinikum Erlangen, Erlangen
Universitätsklinikum Frankfurt, Frankfurt am Main
Universitätsklinikum Freiburg, Freiburg
Universitätsmedizin Göttingen, Göttingen
Universitätsklinikum Hamburg-Eppendorf, Hamburg
Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel
Uniklinik Köln, Köln
Universitätsklinikum Leipzig, Leipzig
Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck
Universitätsklinikum Magdeburg, Magdeburg
Universitätsmedizin Mainz, Mainz
Johannes Wesling Klinikum Minden, Minden
Klinikum der Universität München (LMU), München
Universitätsklinikum Münster, Münster
Sana Klinikum Offenbach GmbH, Offenbach
Klinikum Stuttgart, Stuttgart
Robert-Bosch-Krankenhaus Stuttgart, Stuttgart
Klinikum Mutterhaus, Trier
Universitätsklinikum Würzburg, Würzburg

end of 1:n-Block recruitment locations

start of 1:1-Block recruitment

Recruitment

Planned/Actual: [---]*
(Anticipated or Actual) Date of First Enrollment: 2016/01/31
Target Sample Size: 438
Monocenter/Multicenter trial: Multicenter trial
National/International: National

end of 1:1-Block recruitment

start of 1:1-Block inclusion criteria

Inclusion Criteria

Gender: Both, male and female
Minimum Age: 18 Years
Maximum Age: no maximum age

end of 1:1-Block inclusion criteria

start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Inclusion criteria:

- Histologically verified adenocarcinoma of the esophagus according to the UICC
definition (TNM7)

- Pre-treatment stage cT1N+, M0 or cT2-4a, N0/+, M0

- Age ≥18 years

- No prior abdominal or thoracic radiotherapy

- ECOG Performance status 0-2

- Adequate cardiac function ( Patients with a cardiac history (e.g. myocardial
infarction, heart failure, coronary artery disease) should have a cardiology review)

- Adequate bone marrow function (WBC>3x10^9/l; Hb>9g/dl; platelets >100x10^9/l)

- Adequate respiratory function. Symptomatic Patients should have pulmonary function
tests with FEV1>1,5l )

- Adequate renal function (GFR >60ml/min)

- Adequate liver function (serum bilirubin <1.5x Upper level of Normal (ULN); AST <2.5x
ULN and ALT <3x ULN (ULN as per institutional standard)

- written informed consent

Exclusion Criteria:

- Tumors of squamous or other non-adenocarcinoma histology

- Patients with advanced inoperable or metastatic esophageal adenocarcinoma

- Stage cT1N0 and cT4b

- Gastric carcinoma

- Prior chemotherapy for cancer,

- Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery
disease or myocardial infarction within last 12 months)

- Clinical significant lung disease (FEV 1<1,5l)

- Peripheral neuropathy Grade >1

end of 1:1-Block inclusion criteria add

start of 1:1-Block exclusion criteria

Exclusion Criteria

Exclusion Criteria:

- Tumors of squamous or other non-adenocarcinoma histology

- Patients with advanced inoperable or metastatic esophageal adenocarcinoma

- Stage cT1N0 and cT4b

- Gastric carcinoma

- Prior chemotherapy for cancer,

- Clinically significant (i.e. active) cardiac disease (e.g. symptomatic coronary artery
disease or myocardial infarction within last 12 months)

- Clinical significant lung disease (FEV 1<1,5l)

- Peripheral neuropathy Grade >1

end of 1:1-Block exclusion criteria

start of 1:n-Block addresses

Addresses

Primary Sponsor
start of 1:1-Block address primary-sponsor
- University Hospital Freiburg
end of 1:1-Block address primary-sponsor

start of 1:1-Block address contact primary-sponsor
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact primary-sponsor
Collaborator, Other Address
start of 1:1-Block address other
- Clinical Trials Unit Freiburg
end of 1:1-Block address other

start of 1:1-Block address contact other
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact other
Contact for Scientific Queries
start of 1:1-Block address scientific-contact
- University Hospital Freiburg
- Jens Hoeppner, Professor
end of 1:1-Block address scientific-contact

start of 1:1-Block address contact scientific-contact
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact scientific-contact
Contact for Public Queries
start of 1:1-Block address public-contact
- Jens Hoeppner, Professor
end of 1:1-Block address public-contact

start of 1:1-Block address contact public-contact
- Telephone: +49 761 270-26970
- Fax: [---]*
- E-mail: jens.hoeppner at uniklinik-freiburg.de
- URL: [---]*
end of 1:1-Block address contact public-contact

end of 1:n-Block addresses

start of 1:n-Block material support

Sources of Monetary or Material Support

[---]*
start of 1:1-Block address materialSupport
- Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
end of 1:1-Block address materialSupport

start of 1:1-Block address contact materialSupport
- Telephone: [---]*
- Fax: [---]*
- E-mail: [---]*
- URL: [---]*
end of 1:1-Block address contact materialSupport

end of 1:n-Block material support

start of 1:1-Block state

Status

Recruitment Status: Recruiting ongoing
Study Closing (LPLV): [---]*

end of 1:1-Block state

start of 1:n-Block publications

Trial Publications, Results and other Documents

Further trial documents: ESOPEC Homepage
Further trial documents: Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, Röthling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016 Jul 19;16:503. doi: 10.1186/s12885-016-2564-y.; 27435280

end of 1:n-Block publications

The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .

Translation on version: 210
Last processed date by ClinicalTrials.gov: 2017/12/11

* This entry means the parameter is not applicable or has not been set.